Abeona Therapeutics (ABEO) Stock: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$5.43
0.01 (0.28%)
▲
5d:
-9.5%
30d:
-14.42%
90d:
-1.81%
WAIT
LOW Confidence
Analysis Updated: Sep 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ABEO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ABEO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $5.43, which is considered oversold relative to its 30-day fair value range of $5.61 to $6.76. From a valuation perspective, the stock is trading at a discount (Forward PE: -29.1) compared to its historical average (21.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ABEO is in a uptrend. The price is currently testing key support at $5.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABEO scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.86 (+247.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABEO is in a uptrend. The price is currently testing key support at $5.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABEO scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.86 (+247.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.61 -
$6.76
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 247.3% below Wall St target ($18.86)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.61 -
$6.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.31
Resistance Level
$6.10
Current Trend
Uptrend
Technical data as of
Sep 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.08
Wall Street Target
$18.86
(+247.3%)
Revenue Growth (YoY)
2745.0%
Profit Margin
-246.4%
PE vs Historical
-29.1 vs 21.7
CHEAP
Share & Embed Analysis
Last updated: September 15, 2026 8:33 AM ET
Data refreshes hourly during market hours. Next update: 9:33 AM
Data refreshes hourly during market hours. Next update: 9:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 34 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
